I look forward to hearing from our witnesses, or our witness, on whether the current structure of how Part B drugs are reimbursed--can and should be modified to foster competition ...
We have worked in a bipartisan manner on lowering drug costs over the last several years.
the fact is that there is going to be a lot of resistance if there is an apprehension that a patient can't get the medic...
I would just urge us to try to look for some way where we address this patient choice issue, because I know a lot of my ...
There is some argument that is always made by the pharma companies that if there is some pushback on their pricing power...
we are the only Government that I am aware of that really doesn't play an active role in trying to provide some pricing ...
If we just have these costs go out of control, continue to go out of control, that cuts off access.
I'm amazed. I'm coming home, and they're there delivering the mail. They've been at it for 10 or 12 hours.
It's a practical challenge. That's really what that says.
You're worth it.
It's delightful to have you serving as our chair with your long experience on this committee.